Tesamorelin is a 44-amino-acid analogue of growth hormone-releasing hormone, modified at the N-terminus with a fatty-acid group that changes how long the molecule survives in circulation. It is the longest peptide in the SOMA catalogue outside the incretin agonists, and the one whose structure most clearly illustrates a general principle in peptide design: a single terminal modification can matter more than the other forty-three residues. This guide covers the structure, the receptor, the published research context, and laboratory handling.
SOMA Research supplies tesamorelin for laboratory research use only. It is not a drug, supplement, food or cosmetic, is not approved by the FDA for any use in this form, and is not intended for human or veterinary consumption.
What tesamorelin is
Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone, GHRH(1-44). Published identifiers:
- CAS number: 218949-48-5
- Molecular formula: C221H366N72O67S
- Molecular weight: approximately 5,135.9 g/mol
- Length: 44 amino acids
- Modification: a trans-3-hexenoyl group on the N-terminal tyrosine
- Appearance: white lyophilised powder
The sequence itself is the native human GHRH(1-44) sequence. The engineering is entirely at the N-terminus.
Why the hexenoyl group is the whole design
Native GHRH has a very short circulating half-life, on the order of minutes. The reason is enzymatic: dipeptidyl peptidase-4 cleaves the first two residues from the N-terminus, and GHRH(3-44) does not activate the receptor. Any GHRH analogue intended to persist has to solve that cleavage problem.
Tesamorelin solves it by attaching a six-carbon unsaturated acyl group — trans-3-hexenoyl — to the N-terminal tyrosine. The modification sterically obstructs the DPP-4 recognition site while leaving the receptor-binding determinants intact. The result is a molecule with the same native sequence and a substantially longer functional lifetime.
This is a different strategy from the one used in the incretin peptides. Retatrutide and tirzepatide carry long fatty-diacid chains whose purpose is reversible albumin binding, which slows renal clearance. Tesamorelin’s short hexenoyl group is too small for meaningful albumin binding; it is a protease shield, not an albumin anchor. Two acylated peptides, two entirely different mechanisms for the acyl group. Reading “fatty acid modified” on a datasheet tells you less than it appears to.
The receptor
Tesamorelin acts at the GHRH receptor (GHRHR), a class B G-protein-coupled receptor expressed on somatotroph cells of the anterior pituitary. Receptor activation is coupled to Gs and adenylyl cyclase, raising intracellular cAMP.
The mechanistically interesting feature for research purposes is that this is an upstream intervention. A GHRH analogue acts on the pituitary and leaves the downstream pulsatile release pattern and its feedback loops in place, which is a different experimental proposition from administering growth hormone directly. In preclinical models this distinction is often the point of using a GHRH analogue at all.
Tesamorelin among GHRH analogues
| Compound | Length | Basis | Persistence strategy |
|---|---|---|---|
| GHRH (native) | 44 aa | Endogenous | None — rapid DPP-4 cleavage |
| Sermorelin | 29 aa | GHRH(1-29) fragment | None — short acting |
| Tesamorelin | 44 aa | Full-length GHRH | N-terminal hexenoyl, blocks DPP-4 |
| CJC-1295 | 29 aa | GHRH(1-29) with substitutions | Amino acid substitutions; DAC variant binds albumin |
For comparative receptor work this is a useful panel precisely because the compounds share a receptor and differ in persistence and in sequence length. An effect that tracks with persistence rather than with potency is visible across this set in a way it would not be in a single-compound experiment. SOMA lists CJC-1295 with ipamorelin separately.
Research and regulatory context
Tesamorelin has been the subject of published clinical investigation and a pharmaceutical formulation of the molecule holds regulatory approval in the United States for a specific indication, marketed by its developer. That programme is the developer’s own and concerns a pharmaceutical product manufactured to pharmaceutical standards.
This distinction matters more for tesamorelin than for most of the catalogue, precisely because an approved product exists. Research-grade tesamorelin supplied for laboratory use is not that product. It is not manufactured under pharmaceutical quality systems, it carries no approval of any kind, and it must not be used in or on humans or animals. The existence of an approved pharmaceutical containing the same molecule confers nothing on research-grade material.
Analytical characterisation
A 44-residue peptide is a harder synthesis than a tripeptide, and the analytical requirements scale accordingly:
- HPLC purity. With 44 couplings, the population of deletion and truncation sequences is larger and structurally closer to the target than in a short peptide. Reversed-phase separation is the measurement that resolves them.
- Mass spectrometry. The observed mass should correspond to approximately 5,135.9 g/mol. At this mass, electrospray ionisation produces a multiply charged envelope rather than a single peak, and the reported figure is a deconvoluted mass.
- Confirming the modification. The hexenoyl group contributes approximately 96 Da. An unmodified GHRH(1-44) impurity therefore differs from the target by that amount — close enough that the mass measurement has to be good enough to resolve it, and important enough that it is worth checking, since the unmodified peptide is the one the design exists to avoid.
Every SOMA lot is tested by third-party laboratories using both HPLC and mass spectrometry, with measured figures published per lot in our CoA library. The Certificate of Analysis guide explains how to read those fields.
Handling and storage
- Lyophilised powder: -20°C, protected from light.
- Reconstituted stock: 2–8°C, used within approximately 30 days, aliquoted on reconstitution.
- Handle gently. Longer peptides are more prone to aggregation and to surface adsorption than short ones. Swirl rather than vortex, and direct solvent down the vial wall.
- Watch for adsorption losses. At low concentrations, a meaningful fraction of a long peptide can adsorb to plastic surfaces. Low-binding tubes are worth using for dilute working solutions.
- Avoid freeze-thaw cycling, which is a leading cause of aggregation in peptides of this length.
The procedure and the concentration arithmetic are in our reconstitution guide.
Related guides
Research use only
Research-grade tesamorelin is supplied for laboratory use by qualified researchers and institutions. It is not manufactured to pharmaceutical standards, is not the approved pharmaceutical product, and must not be used in or on humans or animals. Nothing in this guide is medical advice or a representation that the compound is safe or effective for any purpose.
